A systematic review of suggested molecular strata, biomarkers and their tissue sources in ALS
UG Vijayakumar, V Milla, MY Cynthia Stafford… - Frontiers in …, 2019 - frontiersin.org
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is an incurable
neurodegenerative condition, characterized by the loss of upper and lower motor neurons. It …
neurodegenerative condition, characterized by the loss of upper and lower motor neurons. It …
From multi-omics approaches to precision medicine in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a devastating and fatal neurodegenerative disorder,
caused by the degeneration of upper and lower motor neurons for which there is no truly …
caused by the degeneration of upper and lower motor neurons for which there is no truly …
Amyotrophic lateral sclerosis: a focus on disease progression
AC Calvo, R Manzano, DMF Mendonça… - BioMed research …, 2014 - Wiley Online Library
Since amyotrophic lateral sclerosis (ALS) was discovered and described in 1869 as a
neurodegenerative disease in which motor neuron death is induced, a wide range of …
neurodegenerative disease in which motor neuron death is induced, a wide range of …
Imaging neurochemistry and brain structure tracks clinical decline and mechanisms of ALS in patients
OC Andronesi, K Nicholson, K Jafari-Khouzani… - Frontiers in …, 2020 - frontiersin.org
Background: Oxidative stress and protein aggregation are key mechanisms in amyotrophic
lateral sclerosis (ALS) disease. Reduced glutathione (GSH) is the most important …
lateral sclerosis (ALS) disease. Reduced glutathione (GSH) is the most important …
The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure
E Beghi, T Mennini, C Bendotti, P Bigini… - Current medicinal …, 2007 - ingentaconnect.com
Amyotrophic lateral sclerosis (ALS) is a severe clinical condition characterized by upper and
lower motor neuron degeneration for which there is no truly effective treatment. The absence …
lower motor neuron degeneration for which there is no truly effective treatment. The absence …
Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS
Despite major advances in deciphering the neuropathological hallmarks of amyotrophic
lateral sclerosis (ALS), validated neurochemical biomarkers for monitoring disease activity …
lateral sclerosis (ALS), validated neurochemical biomarkers for monitoring disease activity …
Biomarkers for amyotrophic lateral sclerosis
R Bowser, M Cudkowicz… - Expert review of …, 2006 - Taylor & Francis
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease. ALS
is a fatal neurodegenerative disease and clinical diagnosis typically takes many months to …
is a fatal neurodegenerative disease and clinical diagnosis typically takes many months to …
Protein biomarkers for amyotrophic lateral sclerosis
H Ryberg, R Bowser - Expert review of proteomics, 2008 - Taylor & Francis
Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease with largely
unknown pathogenesis that typically results in death within a few years from diagnosis …
unknown pathogenesis that typically results in death within a few years from diagnosis …
Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells
Background Amyotrophic lateral sclerosis (ALS) is a fatal progressive motor neuron disease,
for which there are still no diagnostic/prognostic test and therapy. Specific molecular …
for which there are still no diagnostic/prognostic test and therapy. Specific molecular …
The 'omics' of amyotrophic lateral sclerosis
D Caballero-Hernandez, MG Toscano… - Trends in molecular …, 2016 - cell.com
Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease that primarily
affects motor neurons and is accompanied by sustained unregulated immune responses …
affects motor neurons and is accompanied by sustained unregulated immune responses …